Evofem: Evofem Biosciences : EVFM Presentation at Emerging Growth Conference April 2025

EMERGING GROWTH CONFERENCE APRIL 17, 2025 AMY RASKOPF, CHIEF BUSINESS DEVELOPMENT OFFICER KATHY GALLO-DOYLE, HEAD OF COMMERCIAL OPERATIONS OTC Q B : E V F M F O R W A R D - L O O K I N G S TAT E M E N T S This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws . In some cases, you can identify forward looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "strategy," "objective," "designed," "suggest," "currently," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The rate and degree of market acceptance of PHEXXI® (lactic acid, citric acid and potassium bitartrate) vaginal gel and SOLOSEC® (secnidazole) 2 g oral granules Evofem's ability to successfully commercialize its products in the United States and to enter into successful partnerships to commercialize its products outside of the United States Evofem's estimates regarding expenses, revenues, financial performance and capital requirements, including the length of time its capital resources will sustain its operations, and its ability to raise additional capital to fund its operations when/if needed Evofem's ability to continue as a going concern Evofem's ability to comply with the provisions and requirements of its debt arrangements and to pay amounts owed pursuant to its debt arrangements Evofem's ability to retain members of its management and other key personnel and to expand its organization to accommodate potential growth Evofem's ability to maintain and protect its intellectual property position and its ability to obtain additional patent protection for its product for current and investigational indications The potential for changes to current regulatory mandates requiring payers to cover FDA-approved or -cleared contraceptives without cost sharing Evofem's ability to obtain or maintain third-party payer coverage and adequate reimbursement, and its reliance on the willingness of patients to pay out-of-pocket for its products absent full or partial third-party payer reimbursement Evofem's reliance on third-party providers and licensors, such as third-party manufacturers The presence or absence of any adverse events or side effects relating to the use of its products, and, Any other risk factors detailed in Evofem's filings from time to time with the U.S. Securities and Exchange Commission including, without limitation, the 10-K for the year ended December 31, 2024, filed with the SEC on APRIL 17, 2025, and any subsequent filings. The forward looking statements in this presentation represent Evofem's views only as of the date of this presentation, April 17, 2025, and Evofem expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evofem's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement. This presentation discusses estimates and other statistical data made by independent parties and by Evofem relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. 2 E V O F E M : W O M E N ' S S E X U A L A N D R E P R O D U C T I V E H E A LT H I N N O VAT I O N U.S. biopharma company generating revenues from two FDA-approved innovative products that address unmet needs in women's sexual and reproductive health Birth Control: hormone-free, on-demand prescription contraceptive vaginal gel $19.4M net sales in 2024 Advancing strategy to significantly reduce PHEXXI manufacturing costs Single-dose antimicrobial agent, taken orally FDA-approved to treat bacterial vaginosis (BV) and trichomoniasis Acquired July 2024 and relaunched November 2024 APRIL 17, 2025 3 E V O F E M I S L E A D I N G T H E R E V O L U T I O N Innovative women's reproductive and sexual health solutions ® THE FIRST AND ONLY ON-DEMAND, NON- HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL Vaginal pH Modulator Hormone-free FDA-approved for prevention of pregnancy Woman-controlled Used only when you need it Box of 12 PHEXXI applicators APRIL 17, 2025 4 M O A - P H E X X I I S A p H M O D U L ATO R Optimal vaginal pH levels can range from 3.5 - 4.5 When semen (pH 7.1-8) enters the vagina, it raises the environmental pH level Allows sperm to be mobile and swim up the reproductive canal PHEXXI keeps vaginal pH in the optimal range Among subjects who used PHEXXI in the registrational clinical trials, only 1.6% discontinued due to an adverse reaction. This is lower than published rates of hormonal methods, which range from 9.6% to 20.1% discontinuation due to adverse reactions APRIL 17, 2025 5 P H E X X I ® I N V I T R O D E M O N S T R AT I O N O F S P E R M M OT I L I T Y SPERM WITHOUT PHEXXI IN VITRO SPERM WITH PHEXXI IN VITRO T O V I E W T H E V I D E O , P L E A S E V I S I T H T T P S : / / W W W . Y O U T U B E . C O M / W A T C H ? V = H 8 A O X A N P Z Y Y ( T I M E S T A M P 4 : 2 5 ) 6 4 3 . 3 M P OT E N T I A L P H E X X I U S E R S I N T H E U . S . 1 U.S. MARKET BY CONTRACEPTIVE METHOD 1 O F T H E 7 2 . 7 M W O M E N A G E D 1 5 - 4 9 I N T H E U . S . 10 0% 90 % 80 % 70 % 60 % 50 % 40 % 30 % 20 % 10 % 0% (M ILLIO N S ) Non-Prescription Contraceptive 10.3 No Contraceptive 13.0 Prescription Contraceptive, 20.0 Surgical Sterilization 17.2 Other Non-Targets 12.2 10.3M women use non-prescription contraceptives Non-Rx methods: barrier methods; withdrawal; periodic abstinence; tracking; other 13.0M women use no contraceptive at all 20.0M women use prescription contraceptives Rx hormonal oral contraceptives, rings, patches, shots and IUDs/copper IUD * Study predates commercial availability of PHEXXI $8.3B Contraceptive Market (U.S. 2022) 2 1. Daniels-K-and-Abma-J.-Current-Contraceptive-Status-Among-Women-Aged-15-49_NCHS-Data-Brief-Number-388-October-2020.pdf (evofem.com) APRIL 17, 2025 2. Grandview Research. U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2022 - 2030. 7 E V E R Y 1 % M A R K E T S H A R E I N T H E U . S . A D D R E S S A B L E M A R K E T R E P R E S E N T S S I G N I F I C A N T P H E X X I N E T P R O D U C T S A L E S $362.17 Gross WAC per box of 12 PHEXXI applicators 1 Gross-to-Net adjustments x 5 $470 M boxes of PHEXXI PHEXXI ANNUAL dispensed (on avg.) $217.30 per woman each year NET SALES x 433,000 Net to Evofem per each 1% market penetration 2 per box of PHEXXI women (1% of the 43.3M women in U.S. TAM) (60 PHEXXI applicators) 1. Effective January 1, 2025. WAC: Wholesale Acquisition Cost. APRIL 17, 2025 2. Annual net sales calculation: Net $ to EVFM per box * boxes/year/women * 433,000 women (1% of 43.3M women in PHEXXI addressable market) 8 D E L I V E R I N G O N G O I N G N E T P R O D U C T S A L E S G R O W T H IN MILLIONS $25. 0 $20. 0 $15. 0 $10. 0 $5.0 $- $16.8 $8.2 $19.4 $18.2 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 Launched PHEXXI No marketing spend since Q4 2022 Sept. 2020 APRIL 17, 2025 9 P H E X X I S A L E S C O V E R A G E Field Coverage ( n =16) Virtual Coverage Strategic Initiatives Student Health & Residency Programs APRIL 17, 2025 Attachments Original document Permalink Disclaimer Evofem Biosciences Inc. published this content on April 21, 2025 , and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) , unedited and unaltered, on April 21, 2025 at 19:08 UTC .